CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Blood tests sputum, nasal lavage and brushingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D007154 Immune System Diseases NIH 0.41
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort

DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease

NCT04444609 COVID-19 SARS-CoV 2 ARDS, Human Immune System Disorder Other: Blood tests sputum, nasal lavage and brushing
MeSH:Respiratory Distress Syndrome, Adult Immune System Diseases

Primary Outcomes

Description: Anti-viral cytokine protein concentration in blood samples by ELISA

Measure: Anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Inflammatory cytokine protein concentration in sputum samples by ELISA

Measure: Anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Inflammatory cytokine protein concentration in nasal lavage samples by ELISA

Measure: Anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Inflammatory gene expression in upper airway respiratory epithelial cells by RNA sequencing.

Measure: Expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Secondary Outcomes

Description: Analysis of viral components recognized by the adaptive immune system

Measure: Identify the T cell antigens and B cell epitopes in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Cytokine protein concentration following PBMC stimulation to pathogen recognition receptor agonists by Elispot

Measure: Peripheral blood mononuclear cell (PBMC) interferon mediated immune responses to pathogen recognition receptor agonists in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Analysis of endothelial function

Measure: Identify endothelial function in chronic respiratory disease associated with susceptibility to severe COVID-19 infection using EndoPAT testing

Time: Through study completion an average of 1 year

Description: Serum and plasma protein concentration of endothelial cell inflammation biomarkers by ELISA

Measure: Endothelial cell inflammation biomarkers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Analysis of sputum microbiome

Measure: Identify sputum 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Analysis of nasal microbiome

Measure: Identify nasal lavage 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year

Description: Study participant survey

Measure: Identify quality of life markers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Time: Through study completion an average of 1 year


No related HPO nodes (Using clinical trials)